For instance, if HUGE or the ST procedure predicts FLT3 mutant AML genotypes to be sensitive to FLT3 inhibition, it will be considered a true positive LED, as FLT3 is a well-known target of AML and mutations in FLT3, the fms-like receptor-type tyrosine-protein kinase [25,26], are known to be sensitive biomarkers of the effectiveness of most FLT3-inhibitors [27,28]. Here, FLT3 is linked to acute myeloid leukemia.